Get startedLog in
    Picture of H Lundbeck A/S logo

    HLUN A — H Lundbeck A/S News Story

    0.000.00%
    dk flag iconLast trade - 00:00
    HealthcareBalancedLarge CapSuper Stock
    All News

    Brief: Lundbeck And Otsuka Announce U.S. FDA's Approval Of SNDA For Rexulti® (Brexpiprazole) For The Treatment Of Dementia Due To Alzheimer's Disease

    Picture of H Lundbeck A/S logoH Lundbeck A/S
    11/05/2023 04:40
    May 10 (Reuters) - H Lundbeck A/S  HLUNb.CO :
    * LUNDBECK AND OTSUKA ANNOUNCE U.S. FOOD AND DRUG
ADMINISTRATION
(FDA) APPROVAL OF SNDA FOR REXULTI® (BREXPIPRAZOLE) FOR THE
TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO
ALZHEIMER'S DISEASE

Source text for Eikon:  ID:nWkr86mm7Q 
Further company coverage:  HLUNb.CO 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on H Lundbeck A/S

    See all news